OM
Outset Medical, Inc.
Set alert
- YTD
- +8.63%
- 1 year
- -68.09%
- Open
- 4.02
- Prev close
- 4.19
- Mkt cap
- 75.75M
- Vol
- 81.50K
- Avg vol
- 152.47K
- EPS
- -4.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.90
- High
- 4.15
- Forward P/E
- -0.89
- Beta
- 1.95
- Short ratio
- 2.94
- Inst. own
- 52.16%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 0.82834
- 200-d avg
- 2.07
- 1y target
- 4.00
Key statistics
- Market cap
- 62.00M
- Enterprise value
- 90.03M
- Trailing P/E
- 0.00
- Forward P/E
- -0.89
- PEG ratio
- 0.00
- Price / sales
- 0.54
- Price / book
- 1.30
- EPS (TTM)
- -2.74
- Beta
- 1.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -122.84%
- Revenue (TTM)
- 114.73M
- Revenue growth
- -5.60%
- Free cash flow
- -77.26M
- Total cash
- 175.63M
- Total debt
- 202.08M
- Return on equity
- -141.02%
- Shares outstanding
- 52.54M
- Short % of float
- 6.22%
- 50-day average
- 0.82834
- 200-day average
- 2.07
Analyst view
Consensus: buy
- Target (low)
- 3.00
- Target (mean)
- 4.00
- Target (high)
- 6.00
- Strong buy0
- Buy3
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.405.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.42 | -0.39 | +0.03 | +7.14% |
| Aug 7, 2024 | Jun 1, 2024 | -0.43 | -0.47 | -0.04 | -9.30% |
| Aug 7, 2024 | Jun 1, 2024 | -0.43 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.53 | -0.57 | -0.04 | -7.55% |
| May 8, 2024 | Mar 1, 2024 | -0.53 | — | — | — |
| Feb 21, 2024 | Dec 1, 2023 | -0.61 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2024 | RBC Capital | down | Outperform | Sector Perform |
| Aug 8, 2024 | TD Cowen | main | Buy | Buy |
| Jun 21, 2024 | RBC Capital | up | Sector Perform | Outperform |
| Apr 8, 2024 | BTIG | init | — | Buy |
| Jan 12, 2024 | RBC Capital | down | Outperform | Sector Perform |
| Dec 4, 2023 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Outset Medical, Inc.
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- outsetmedical.com
News
- Outset Medical to Participate in the 2026 Stifel Healthcare Conference
- Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
- Full Transcript: Outset Medical Q2 2026 Earnings Call
- Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock
- Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript
- Outset Medical Q2 Earnings Call Highlights
- Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates
- Outset Medical Affirms FY2026 Sales Guidance of $125.000M-$130.000M vs $126.633M Est
- Outset Medical Q2 Adj. EPS $(0.80) Misses $(0.72) Estimate, Sales $31.635M Beat $29.833M Estimate
- Outset Medical Reports Second Quarter 2026 Results
Your note
Sign in to keep a note on OM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AHMED NABEEL | Chief Financial Officer | Sale | Nov 14, 2024 | 310,767 |
| BROTTEM JOHN L. | General Counsel | Sale | Nov 14, 2024 | 227,092 |
| DREXLER KAREN | Director | Stock Award(Grant) | May 28, 2024 | 48,232 |
| GROSSMAN DONALD KEITH | Director | Conversion of Exercise of derivative security | Jun 2, 2024 | 79,221 |
| HACKETT PATRICK T. | Director | Stock Award(Grant) | May 28, 2024 | 42,849 |
| HINRICHS JAMES F | Director | Stock Award(Grant) | May 28, 2024 | 80,349 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 9.09% | 4,773,776 | 5.63M | Sep 29, 2024 |
| Vanguard Group Inc | 5.03% | 2,644,534 | 3.12M | Sep 29, 2024 |
| Millennium Management Llc | 3.59% | 1,888,424 | 2.23M | Sep 29, 2024 |
| Ameriprise Financial, Inc. | 3.45% | 1,810,234 | 2.14M | Sep 29, 2024 |
| GMT Capital Corp | 2.80% | 1,471,706 | 1.74M | Sep 29, 2024 |
| Mubadala Investment Co PJSC | 2.74% | 1,440,601 | 1.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Medical Technology & Devices Port | 6.28% | 3,300,000 | 3.89M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 3.14% | 1,647,932 | 1.94M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.43% | 753,842 | 889.53K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 293,310 | 346.11K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.45% | 238,407 | 281.32K | Aug 30, 2024 |
| Morgan Stanley Inst Fund Inc-Inception Port | 0.37% | 196,183 | 231.50K | Sep 29, 2024 |